Trinity Capital committed $45 million in growth capital to Neurolens, a company commercializing solutions to optimize vision.
Neurolens recently launched N3, a solution for eyecare providers to measure eye misalignment down to a fraction of a prism diopter. The capital from Trinity Capital will fuel continued growth in the company’s operations and is expected to further accelerate the adoption of its N3 devices in optometry practices across the U.S. and Canada.
“With the introduction of the N3, Neurolens will enable even more eye care professionals to access contoured prism technology in their optometry practices,” Igor DaCruz, managing director of life sciences at Trinity Capital, said. “We are thrilled to work with them as they continue changing the lives of patients.”
“While we continue to experience double-digit growth each year, the unmet patient need remains immense,” Davis Corley, executive chairman of Neurolens. said. “We are committed to leveraging innovative technology like the N3 to remove barriers to adoption and ensure that every eye care professional can access these life-changing outcomes for their patients. We are grateful that Trinity Capital Inc. — along with our dedicated investors — are embracing our mission to transform eye care.”
